The study, published in The Lancet, evaluated the pharmacokinetics, safety and tolerability of two intramuscular formations of lenacapavir in participants ages 18-55 without HIV.
Results showed that a single 5,000-milligram intramuscular dose maintained drug concentrations above levels associated with efficacy in previous phase 3 trials for at least 56 weeks.
Compared to the currently studied biannual subcutaneous version, the annual formulation achieved higher plasma concentrations, suggesting potential for long-lasting HIV prevention.